OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
William Yang Wang, QuangQiu Wang, Xin Qi, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 15
William Yang Wang, QuangQiu Wang, Xin Qi, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 15
Showing 15 citing articles:
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Drug Repurposing using Artificial Intelligence, Molecular Docking, and Hybrid Approaches: A Comprehensive Review in General Diseases vs Alzheimer's Disease
Natasha Azeelen Zulhafiz, Teoh Teik Toe, Ai‐Vyrn Chin, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 261, pp. 108604-108604
Closed Access
Natasha Azeelen Zulhafiz, Teoh Teik Toe, Ai‐Vyrn Chin, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 261, pp. 108604-108604
Closed Access
Response to the letter titled “Analysis of semaglutide's effect on Alzheimer's disease risk”
Rong Xu
Alzheimer s & Dementia (2025)
Open Access
Rong Xu
Alzheimer s & Dementia (2025)
Open Access
Pleotropic Effects of Glucose-Lowering Medications—Need for Cautious Interpretation of Target Trial Emulation Studies
Nathan M. Stall, Timothy S. Anderson, Kenneth E. Covinsky
JAMA Internal Medicine (2025)
Closed Access
Nathan M. Stall, Timothy S. Anderson, Kenneth E. Covinsky
JAMA Internal Medicine (2025)
Closed Access
Reply to “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US”
Michael G. Rydberg
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Michael G. Rydberg
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Response to the letter titled reply to “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US”
Rong Xu
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Rong Xu
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus
Robert Perneczky, David Darby, Giovanni B. Frisoni, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100096-100096
Open Access
Robert Perneczky, David Darby, Giovanni B. Frisoni, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100096-100096
Open Access
Rodent islet amyloid polypeptide (IAPP) selectively enhances GABAA receptor-mediated neuronal inhibition in mouse ventral but not dorsal hippocampal dentate gyrus granule cells
Olga Netsyk, Sergiy V. Korol, Gunilla T. Westermark, et al.
Frontiers in Cellular Neuroscience (2025) Vol. 19
Open Access
Olga Netsyk, Sergiy V. Korol, Gunilla T. Westermark, et al.
Frontiers in Cellular Neuroscience (2025) Vol. 19
Open Access
Insight into the etiology of Alzheimer's disease from GLP‐1R knockout mice: Commentary on “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes”
Garth J. Thompson
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Garth J. Thompson
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia
Daniela Ceccarelli Ceccarelli, S. B. Solerte
Metabolites (2025) Vol. 15, Iss. 3, pp. 159-159
Open Access
Daniela Ceccarelli Ceccarelli, S. B. Solerte
Metabolites (2025) Vol. 15, Iss. 3, pp. 159-159
Open Access
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease
Dongming Liu, Hongbao Cao, Ancha Baranova, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100129-100129
Open Access
Dongming Liu, Hongbao Cao, Ancha Baranova, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100129-100129
Open Access
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access
From Gut to Brain: The Role of Gut Dysbiosis, Bacterial Amyloids, and Metabolic Disease in Alzheimer’s Disease
Saadet Inan, R. Paul Wilson, Çağla Tükel
Pharmacological Research (2025), pp. 107693-107693
Open Access
Saadet Inan, R. Paul Wilson, Çağla Tükel
Pharmacological Research (2025), pp. 107693-107693
Open Access
Alzheimer’s disease: What treatments could be rolled out in the next few years?
Elisabeth Mahase
BMJ (2024), pp. q2477-q2477
Closed Access
Elisabeth Mahase
BMJ (2024), pp. q2477-q2477
Closed Access
Analysis of semaglutide's effect on Alzheimer's disease risk
Chi‐Kuei Hsu, Chih‐Cheng Lai
Alzheimer s & Dementia (2024)
Open Access
Chi‐Kuei Hsu, Chih‐Cheng Lai
Alzheimer s & Dementia (2024)
Open Access
